Pulmonary hypertension. Pathophysiology and current concepts of medication therapy;Pulmonale Hypertonie. Pathophysiologie und aktuelle medikamentöse Therapiekonzepte

Anaesthesist

Volumn 53, Issue 8, 2004, Pages 734-740

  Wilkens, H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Pathophysiology; Pulmonary hypertension; Treatment

Indexed keywords

ADENOSINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM ANTAGONIST; CYCLOSPORIN A; DIGITALIS; DIHYDRALAZINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLIBENCLAMIDE; ILOPROST; NITRATE; NITRIC OXIDE; PHENPROCOUMON; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SPIRONOLACTONE; UNIPROST; WARFARIN;

ANGIOGENESIS; CLINICAL TRIAL; DISEASE CLASSIFICATION; EXERCISE; HEART RIGHT VENTRICLE FAILURE; HUMAN; INFLAMMATION; ITALY; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG ENDOTHELIUM; PATHOPHYSIOLOGY; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; THROMBOSIS; VASOCONSTRICTION; VASODILATATION; WORLD HEALTH ORGANIZATION;

ANTICOAGULANTS; DIGITALIS GLYCOSIDES; DIURETICS; HUMANS; HYPERTENSION, PULMONARY; VASODILATOR AGENTS;

EID: 4344699038     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-004-0713-1     Document Type: Review

References (30)

1. Archer S, Rich S (2000) Primary pulmonary hypertension: a vascular biology and translational research "work in progress". Circulation 102:2781-2791
2. Barst RJ, Rubin LJ, Long WA et al. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. New Engl J Med 334:296-302
3. British Cardiac Society Guidelines and Medical Practice Committee (2001) Recommendations on the management of pulmonary hypertension in clinical practice. Heart 86 [Suppl 1]:1-13
4. Channick RN, Simonneau G, Sitbon O (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119-1123
5. Chen YF, Oparil S (2000) Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 320:223-232
6. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. New Engl J Med 327:70-75
7. D'Alonzo GE, Barst RJ, Ayres SM et al. (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343-349
8. Du L, Sullivan CC, Chu D et al. (2003) Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348:500-509
9. Fuster V, Steele PM, Edwards WO, Gersh BJ, McGoon MD, Frye RL (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70:580-587
10. Galie N, Humbert M, Vachiery JL et al. (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496-1502
11. Ghofrani HA, Wiedemann R, Rose F et al. (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360:895-900
12. Giaid A (1998) Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 114:208S-212S
13. Hoeper MM, Schwarze M, Ehlerding S et al. (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. New Engl J Med 342:1866-1870
14. Janssen B, Rindermann M, Barth U et al. (2002) Linkage analysis in a large family with primary pulmonary hypertension: genetic heterogeneity and a second primary pulmonary hypertension locus on 2q31-32. Chest 121:54S-56S
15. Lane KB, Machado RD, Pauciulo MW et al. (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 26:81-84
16. Magnussen H, Goeckenjan G, Kohler O, Matthys H, Morr H, Worth H, Wuthe H (2001) Leitlinien zur Langzeit-Sauerstofftherapie. Pneumologie 55:454-464
17. McLaughlin VV, Genthner DE, Panella MM, Rich S (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension [see comments]. New Engl J Med 338:273-277
18. Nocturnal Oxygen Therapy Trial Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 93:391-398
19. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W (1996) Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124:820-824
20. Olschewski H, Ghofrani HA, Schmehl T et al. (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 132:435-443
21. Olschewski H, Olschewski A, Rose F et al. (2001) Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 138:287-297
22. Olschewski H, Simonneau G, Galie N et al. (2002) Inhaled iloprost for severe pulmonary hypertension. New Engl J Med 347:322-329
23. Rich S (1998) Clinical insights into the pathogenesis of primary pulmonary hypertension. Chest 114:237S-241S
24. Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension [see comments]. New Engl J Med 327:76-81
25. Rubin LJ (2001) Therapy of pulmonary hypertension: targeting pathogenic mechanisms with selective treatment delivery. Crit Care Med 29:1086-1087
26. Rubin LJ, Badesch DB, Barst RJ et al. (2002) Bosentan therapy for pulmonary arterial hypertension. New Engl J Med 346:896-903
27. Simonneau G, Barst RJ, Galie N et al. (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800-804
28. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF (2001) The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 22:405-418
29. Watkins WD, Peterson MB, Crone RK, Shannon DC, Levine L (1980) Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension. Lancet 1:1083
30. Wilkens H, Guth A, Konig J et al. (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218-1222